No Data
No Data
Chongqing Pharscin Pharmaceutical (SZSE:002907) Investors Are up 16% in the Past Week, but Earnings Have Declined Over the Last Three Years
Chongqing Pharscin Pharmaceutical (002907.SZ) now has four self-developed innovative drugs of cancer class 1.1 under research.
Chongqing Pharscin Pharmaceutical (002907.SZ) stated on the investor interaction platform on July 31 that the company now has four independently developed class 1.1 innovative drugs for tumor research projects, with potential indications covering tumor immunity, as well as various solid tumors such as lung cancer, breast cancer, colorectal cancer, pancreatic cancer, etc. Currently, with the progress of project research and development, some projects have been made public or submitted for compound patent applications. The company will also continue to orderly promote the development of research projects under the premise of risk control.
Chongqing Pharscin Pharmaceutical (002907.SZ): The standardized planting base for Atractylodes macrocephala established in Youyang County, Chongqing, covers an area of over one hundred acres.
Chongqing Pharscin Pharmaceutical (002907.SZ) stated on its investor interaction platform on July 29th that the company has established a standardized planting base for Atractylodes macrocephala in Youyang County, Chongqing, covering an area of over 100 mu.
Chongqing Pharscin Pharmaceutical (002907.SZ): Currently, the company does not have any traditional Chinese medicine related products for diabetes.
Chongqing Pharscin Pharmaceutical (002907.SZ) stated on the investor interactive platform on July 29th that the company currently has no traditional Chinese medicine products related to diabetes.
Chongqing Pharscin Pharmaceutical's Omeprazole Sodium for Injection Completes Registration With Chinese Drug Regulator
Chongqing Pharscin Pharmaceutical (002907.SZ): Intravenous Omeprazole Sodium Completes Domestic Production Drug Filing.
Chongqing Pharscin Pharmaceutical (002907.SZ) announced on July 24th that the company recently learned from the website of the National Medical Products Administration that its product, injection-grade omeprazole sodium, has completed domestic drug registration (application for extension of drug validity), and the registration information has been publicly displayed on the website of the National Medical Products Administration. Injection-grade omeprazole sodium is a classic medication for upper gastrointestinal bleeding and is clinically necessary. It is a product on the national medical insurance list and has been recommended in multiple guidelines. It is the only proton pump inhibitor that has entered the national essential drug list and has a wide range of applications.
No Data